Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Harold E Bays. (2014) Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. International Journal of General Medicine 7, pages 355-364.
Read now
Read now
Linda Dayer-Berenson, Mary Finckenor & Michelle Tuzzolino. (2014) Are add-on agents to statin therapy necessary in hypercholesterolemia?. Clinical Lipidology 9:6, pages 695-707.
Read now
Read now
Matilda Florentin, Michael S Kostapanos, Anastazia Kei & Moses S Elisaf. (2014) Emerging drugs for hyperlipidaemia: an update. Expert Opinion on Emerging Drugs 19:4, pages 471-488.
Read now
Read now
Lisa M Younk & Stephen N Davis. (2012) Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 8:4, pages 515-525.
Read now
Read now
Michael S. Kostapanos, Vasilios G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2012) Therapeutic options for statin-intolerant patients. Current Medical Research and Opinion 28:3, pages 345-349.
Read now
Read now
PradeepK. Dhal, DiegoA. Gianolio & RobertJ. Miller. (2011) (Bio)polymeric Hydrogels as Therapeutic Agents. Journal of Macromolecular Science, Part A 48:12, pages 994-1003.
Read now
Read now
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis & Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, pages 247-270.
Read now
Read now
Nkechinyere Ijioma & Jennifer G Robinson. (2011) Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Review of Cardiovascular Therapy 9:2, pages 131-145.
Read now
Read now
Vasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis & Dimitri P Mikhailidis. (2008) Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. Expert Opinion on Investigational Drugs 17:12, pages 1777-1779.
Read now
Read now
Evangelos N Liberopoulos, Matilda Florentin, Dimitri P Mikhailidis & Moses S Elisaf. (2008) Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opinion on Drug Safety 7:6, pages 717-725.
Read now
Read now
Articles from other publishers (22)
Muhammad Shahidul Islam, Anjiya Sharif, Nathania Kwan & Kam C. Tam. (2022) Bile Acid Sequestrants for Hypercholesterolemia Treatment Using Sustainable Biopolymers: Recent Advances and Future Perspectives. Molecular Pharmaceutics 19:5, pages 1248-1272.
Crossref
Crossref
A. J. Cupido, R. M. Stoekenbroek & J. J. P. Kastelein. 2020. Clinical Cardiogenetics. Clinical Cardiogenetics
387
411
.
Theodosios D. Filippatos, Thalia Panagiotopoulou, Eleftheria Tzavella & Moses S. Elisaf. (2018) Hypolipidemic Drugs and Diabetes Mellitus—Mechanisms and Data From Genetic Trials. Journal of Cardiovascular Pharmacology and Therapeutics 23:3, pages 187-191.
Crossref
Crossref
A. J. Cupido, R. M. Stoekenbroek & J. J. P. Kastelein. 2016. Clinical Cardiogenetics. Clinical Cardiogenetics
331
354
.
Shamsa Ali & Vivian Fonseca. 2015. International Textbook of Diabetes Mellitus. International Textbook of Diabetes Mellitus
758
764
.
Alberico L. Catapano, Michel Farnier, JoAnne M. Foody, Peter P. Toth, Joanne E. Tomassini, Philippe Brudi & Andrew M. Tershakovec. (2014) Combination therapy in dyslipidemia: Where are we now?. Atherosclerosis 237:1, pages 319-335.
Crossref
Crossref
Ling He, Prachi Wickremasingha, James Lee, Ben Tao, Jeanne Mendell-Harary, Joseph Walker & Douglas Wight. (2014) Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. Diabetes Research and Clinical Practice 104:3, pages 401-409.
Crossref
Crossref
Nicolas Bertrand, Patrick Colin, Maxime Ranger & Jeanne Leblond. 2013. Supramolecular Systems in Biomedical Fields. Supramolecular Systems in Biomedical Fields
483
517
.
Olov Wiklund, Carlo Pirazzi & Stefano Romeo. (2013) Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy. Current Cardiology Reports 15:9.
Crossref
Crossref
Matilda FlorentinEvangelos N. LiberopoulosChristos V. RizosAnastazia A. KeiGeorge LiamisMichael S. KostapanosMoses S. Elisaf. (2013) Colesevelam Plus Rosuvastatin 5 mg/Day Versus Rosuvastatin 10 mg/Day Alone on Markers of Insulin Resistance in Patients with Hypercholesterolemia and Impaired Fasting Glucose. Metabolic Syndrome and Related Disorders 11:3, pages 152-156.
Crossref
Crossref
Elisavet Moutzouri, Vasilis Tsimihodimos, Evangelos Rizos & Moses Elisaf. (2011) Prediabetes: To treat or not to treat?. European Journal of Pharmacology 672:1-3, pages 9-19.
Crossref
Crossref
A. Bakker, L. Jakulj & J. J. P. Kastelein. 2011. Clinical Cardiogenetics. Clinical Cardiogenetics
305
330
.
Joseph E. Thomas, Andrew M. Tershakovec, Charlotte Jones-Burton, Reza A. Sayeed & JoAnne M. Foody. (2010) Lipid Lowering for Secondary Prevention of Cardiovascular Disease in Older Adults. Drugs & Aging 27:12, pages 959-972.
Crossref
Crossref
Roeland Huijgen, Evertine J. Abbink, Eric Bruckert, Anton F.H. Stalenhoef, Ben P.M. Imholz, Paul N. Durrington, M.D. Trip, Mats Eriksson, Frank L.J. Visseren, Juergen R. Schaefer & John J.P. Kastelein. (2010) Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: A 12-week, multicenter, randomized, double-blind, controlled trial. Clinical Therapeutics 32:4, pages 615-625.
Crossref
Crossref
A.H. Pijlman, R. Huijgen, S.N. Verhagen, B.P.M. Imholz, A.H. Liem, J.J.P. Kastelein, E.J. Abbink, A.F.H. Stalenhoef & F.L.J. Visseren. (2010) Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 209:1, pages 189-194.
Crossref
Crossref
Željko Reiner. (2010) Combined therapy in the treatment of dyslipidemia. Fundamental & Clinical Pharmacology 24:1, pages 19-28.
Crossref
Crossref
Frederick J. Suchy. 2010. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease
1045
1066.e5
.
Pradeep K. Dhal, Steven C. Polomoscanik, Louis Z. Avila, S. Randall Holmes-Farley & Robert J. Miller. (2009) Functional polymers as therapeutic agents: Concept to market place. Advanced Drug Delivery Reviews 61:13, pages 1121-1130.
Crossref
Crossref
Prasanth N Surampudi, Prathima Nagireddy & Vivian A Fonseca. (2009) Colesevelam hydrochloride: a bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus. Therapy 6:4, pages 475-487.
Crossref
Crossref
. (2009) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 16:2, pages 189-202.
Crossref
Crossref
Konstantinos Tziomalos, Vasilios G Athyros & Dimitri P Mikhailidis. (2008) Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. Nature Clinical Practice Endocrinology & Metabolism 5:1, pages 16-17.
Crossref
Crossref
Allison B Goldfine. (2008) Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Current Opinion in Cardiology 23:5, pages 502-511.
Crossref
Crossref